InspireMD Posts $13.7M Q1 Net Loss Despite 122% Revenue Growth; Details Recall Costs
summarizeSummary
InspireMD reported Q1 2026 results, showing a 122% year-over-year revenue increase to $3.4 million, but also a substantial net loss of $13.7 million. The company also announced FDA IDE approval to initiate the CGUARDIANS III clinical trial. This earnings report follows the May 1st news of a voluntary recall for its CGuard Prime 135 cm delivery system and the withdrawal of full-year 2026 revenue guidance, with the report now detailing approximately $1.35 million in associated recall costs. The significant net loss, representing a material portion of the company's market capitalization, exacerbates concerns raised by the 'going concern' warning in its last 10-K. While strong revenue growth and new trial approvals are positive, the persistent unprofitability and the impact of the recall are likely to weigh heavily on investor sentiment. Traders will be watching for improvements in profitability and further updates on product development and regulatory approvals.
At the time of this announcement, NSPR was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $54.9M. The 52-week trading range was $1.04 to $2.93. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.